Repligen Corporation Establishes Allegro Biologics

Repligen Corporation, a global biopharmaceutical company, has launched Allegro Biologics, a strategic business unit focused on process development and manufacturing. The new division, led by Ashley Lawton, Ph.D., marks a significant expansion of Repligen's capabilities in the biotechnology and pharmaceutical industries. Allegro Biologics is poised to capitalize on the trend of "virtual biotechnology companies" outsourcing manufacturing needs. With a strong track record of developing high-quality proteins for human clinical trials, Repligen is well-positioned to meet the growing demand for contract manufacturing services.

Key Takeaways:

• Repligen Corporation has established Allegro Biologics, a new strategic business unit focused on process development and contract manufacturing services.
• Allegro Biologics is led by Ashley Lawton, Ph.D., a 36-year-old biochemist with extensive experience in operations management, sales, and marketing.
• The new division is in advanced discussions with biotechnology and pharmaceutical companies seeking high-quality process development and manufacturing services.
• Repligen established Allegro Biologics in 1995 to respond to growing demand for contract manufacturing services in the biotechnology and pharmaceutical industries.
• Allegro Biologics will capitalize on the trend of "virtual biotechnology companies" outsourcing manufacturing needs, with industry analysts predicting significant growth in the use of contract manufacturing services.
• The new division has a competitive advantage in process development expertise, quality control infrastructure, and efficient, systematic approach to protein product production.
• Repligen Corporation identifies breakthrough technologies, engages in value-added product research, and forms strategic marketing alliances to expedite the commercialization of cost-effective therapeutics.

Statistics:

• 1995: Repligen established Allegro Biologics to meet growing demand for contract manufacturing services in the biotechnology and pharmaceutical industries.
• 36: Ashley Lawton's age at the time of appointment as General Manager of Allegro Biologics Division.
• 100%: Allegro Biologics has already executed its first contract to purify monoclonal antibodies intended for human clinical trials.
• 1: Industry analysts predict that the trend towards "virtual biotechnology companies" outsourcing manufacturing needs will continue to accelerate, leading to significant growth in the use of contract manufacturing services.

Sources:

• PRNewswire, May 9, 1995
• Repligen Corporation press release, May 1995